The AZURE trial data add to the uncertainty of whether adjuvant bisphophonates are a valuable addition to the armamentarium in the treatment of early stage breast cancer. Although the overall trial results were negative, a prespecified subgroup analysis demonstrated a 25% reduction in the risk of relapse and death in postmenopausal patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coleman, R. E. et al. Breast cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 365, 1396–1405 (2011).
Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679–691 (2009).
Gnant, M. et al. Overall survival with adjuvant zoledronic acid in premenopausal breast cancer patients with complete endocrine blockade—long-term results from ABCSG-12 [abstract]. J. Clin. Oncol. 29 (Suppl.), a520 (2011).
Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 133, 571–573 (1889).
Gnant, M. & Clézardin, P. Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature. Cancer Treat. Rev. http://dx.doi.org/10.1016/j.ctrv.2011.09.003.
Eidtmann, H. et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann. Oncol. 21, 2188–2194 (2010).
Coleman, R. E. et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer 102, 1099–1105 (2010).
Aft, R. et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 11, 421–428 (2010).
Chlebowski, R. T. & Col, N. Bisphosphonates and breast cancer prevention. Anticancer Agents Med. Chem. http://dx.doi.org/BSP/ACAMC/E-Pub/00051.
Gallo, M., De Luca, A., Lamura, L. & Normanno, N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdr159.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
M. Gnant has received research support from and has served as a consultant for AstraZeneca, Novartis, and Pfizer, and has received lecture fees and honoraria for participation on advisory boards from Amgen, AstraZeneca, Novartis, Pfizer, Roche, Sanofi-Aventis and Schering.
Rights and permissions
About this article
Cite this article
Gnant, M. Adjuvant bisphosphonates—an option with low estrogen?. Nat Rev Clin Oncol 8, 698–699 (2011). https://doi.org/10.1038/nrclinonc.2011.170
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.170
